APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hospital-Acquired Pneumonia (HAP) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hospital-Acquired Pneumonia (HAP) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173999210322 December 2025199 pages

Choose your research edition.

Industry ResearchHospital-Acquired Pneumonia (HAP) Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Hospital-Acquired Pneumonia (HAP) Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hospital-Acquired Pneumonia (HAP) Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hospital-Acquired Pneumonia (HAP) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hospital-Acquired Pneumonia (HAP) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs include Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Novartis, Merck, Mylan, Pfizer, AstraZeneca, Theravance Biopharma and The Medicines Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hospital-Acquired Pneumonia (HAP) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hospital-Acquired Pneumonia (HAP) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hospital-Acquired Pneumonia (HAP) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hospital-Acquired Pneumonia (HAP) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Company

Teva Pharmaceutical Industries

Sun Pharmaceutical Industries

Novartis

Merck

Mylan

Pfizer

AstraZeneca

Theravance Biopharma

The Medicines Company

Shinogi

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Type

Antiviral

Antibacterial

Antifungal

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Application

Hospitals

Clinics

Others

Hospital-Acquired Pneumonia (HAP) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital-Acquired Pneumonia (HAP) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hospital-Acquired Pneumonia (HAP) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital-Acquired Pneumonia (HAP) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hospital-Acquired Pneumonia (HAP) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hospital-Acquired Pneumonia (HAP) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hospital-Acquired Pneumonia (HAP) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hospital-Acquired Pneumonia (HAP) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends Table 2. Hospital-Acquired Pneumonia (HAP) Drugs Industry Drivers Table 3. Hospital-Acquired Pneumonia (HAP) Drugs Industry Opportunities and Challenges Table 4. Hospital-Acquired Pneumonia (HAP) Drugs Industry Restraints Table 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Manufacturers Table 9. Global Hospital-Acquired Pneumonia (HAP) Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Hospital-Acquired Pneumonia (HAP) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers, Product Type & Application Table 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hospital-Acquired Pneumonia (HAP) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Antiviral Table 17. Major Manufacturers of Antibacterial Table 18. Major Manufacturers of Antifungal Table 19. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2026) & (k units) Table 21. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2027-2032) & (k units) Table 22. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2021-2026) Table 23. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2027-2032) Table 24. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2021-2026) & (k units) Table 26. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2027-2032) & (k units) Table 27. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Clinics Table 31. Major Manufacturers of Others Table 32. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2026) & (k units) Table 34. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2027-2032) & (k units) Table 35. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2021-2026) Table 36. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2027-2032) Table 37. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2021-2026) & (k units) Table 39. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2027-2032) & (k units) Table 40. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2021-2026) & (k units) Table 44. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2021-2026) Table 45. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 49. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 50. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 52. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2027-2032) & (k units) Table 59. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2027-2032) Table 64. Teva Pharmaceutical Industries Company Information Table 65. Teva Pharmaceutical Industries Business Overview Table 66. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 68. Teva Pharmaceutical Industries Recent Development Table 69. Sun Pharmaceutical Industries Company Information Table 70. Sun Pharmaceutical Industries Business Overview Table 71. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 73. Sun Pharmaceutical Industries Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 78. Novartis Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 83. Merck Recent Development Table 84. Mylan Company Information Table 85. Mylan Business Overview Table 86. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 88. Mylan Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 93. Pfizer Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 98. AstraZeneca Recent Development Table 99. Theravance Biopharma Company Information Table 100. Theravance Biopharma Business Overview Table 101. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 103. Theravance Biopharma Recent Development Table 104. The Medicines Company Company Information Table 105. The Medicines Company Business Overview Table 106. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 108. The Medicines Company Recent Development Table 109. Shinogi Company Information Table 110. Shinogi Business Overview Table 111. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio Table 113. Shinogi Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Hospital-Acquired Pneumonia (HAP) Drugs Distributors List Table 117. Hospital-Acquired Pneumonia (HAP) Drugs Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Hospital-Acquired Pneumonia (HAP) Drugs Product Image Figure 2. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (2021-2032) & (k units) Figure 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Hospital-Acquired Pneumonia (HAP) Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Antiviral Image Figure 9. Antibacterial Image Figure 10. Antifungal Image Figure 11. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 40. China Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Hospital-Acquired Pneumonia (HAP) Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Hospital-Acquired Pneumonia (HAP) Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Antiviral
  • Antibacterial
  • Antifungal
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Novartis
  • Merck
  • Mylan
  • Pfizer
  • AstraZeneca
  • Theravance Biopharma
  • The Medicines Company
  • Shinogi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Dynamics
  1. 2.1 Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends
  2. 2.2 Hospital-Acquired Pneumonia (HAP) Drugs Industry Drivers
  3. 2.3 Hospital-Acquired Pneumonia (HAP) Drugs Industry Opportunities and Challenges
  4. 2.4 Hospital-Acquired Pneumonia (HAP) Drugs Industry Restraints
3 Hospital-Acquired Pneumonia (HAP) Drugs Market by Manufacturers
  1. 3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hospital-Acquired Pneumonia (HAP) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hospital-Acquired Pneumonia (HAP) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hospital-Acquired Pneumonia (HAP) Drugs Tier 1, Tier 2, and Tier 3
4 Hospital-Acquired Pneumonia (HAP) Drugs Market by Type
  1. 4.1 Hospital-Acquired Pneumonia (HAP) Drugs Type Introduction
  2. 4.1.1 Antiviral
  3. 4.1.2 Antibacterial
  4. 4.1.3 Antifungal
  5. 4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type
  6. 4.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type
  10. 4.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2021-2032)
5 Hospital-Acquired Pneumonia (HAP) Drugs Market by Application
  1. 5.1 Hospital-Acquired Pneumonia (HAP) Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application
  6. 5.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application
  10. 5.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2021-2032)
6 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region
  1. 6.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region
  1. 7.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region
  2. 7.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2032)
  8. 7.2.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries
  2. 8.1.1 Teva Pharmaceutical Industries Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 8.2 Sun Pharmaceutical Industries
  8. 8.2.1 Sun Pharmaceutical Industries Company Information
  9. 8.2.2 Sun Pharmaceutical Industries Business Overview
  10. 8.2.3 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Industries Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Theravance Biopharma
  44. 8.8.1 Theravance Biopharma Company Information
  45. 8.8.2 Theravance Biopharma Business Overview
  46. 8.8.3 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  48. 8.8.5 Theravance Biopharma Recent Developments
  49. 8.9 The Medicines Company
  50. 8.9.1 The Medicines Company Company Information
  51. 8.9.2 The Medicines Company Business Overview
  52. 8.9.3 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  54. 8.9.5 The Medicines Company Recent Developments
  55. 8.10 Shinogi
  56. 8.10.1 Shinogi Company Information
  57. 8.10.2 Shinogi Business Overview
  58. 8.10.3 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
  60. 8.10.5 Shinogi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hospital-Acquired Pneumonia (HAP) Drugs Value Chain Analysis
  2. 9.1.1 Hospital-Acquired Pneumonia (HAP) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hospital-Acquired Pneumonia (HAP) Drugs Production Mode & Process
  6. 9.2 Hospital-Acquired Pneumonia (HAP) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hospital-Acquired Pneumonia (HAP) Drugs Distributors
  9. 9.2.3 Hospital-Acquired Pneumonia (HAP) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst